230 related articles for article (PubMed ID: 16778827)
1. Decreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: lessons learned from vitiligo.
Singh ZN; Tretiakova MS; Shea CR; Petronic-Rosic VM
Mod Pathol; 2006 Sep; 19(9):1255-60. PubMed ID: 16778827
[TBL] [Abstract][Full Text] [Related]
2. Loss of melanocytes in hypopigmented mycosis fungoides: a study of 18 patients.
Furlan FC; de Paula Pereira BA; da Silva LF; Sanches JA
J Cutan Pathol; 2014 Feb; 41(2):101-7. PubMed ID: 24219812
[TBL] [Abstract][Full Text] [Related]
3. Thymocyte selection-associated high-mobility group box as a potential diagnostic marker differentiating hypopigmented mycosis fungoides from early vitiligo: A pilot study.
Ibrahim MA; Mohamed A; Soltan MY
Indian J Dermatol Venereol Leprol; 2021; 87(6):819-825. PubMed ID: 31857520
[TBL] [Abstract][Full Text] [Related]
4. Hypopigmented Mycosis Fungoides Mimicking Vitiligo.
Kim JC; Kim YC
Am J Dermatopathol; 2021 Mar; 43(3):213-216. PubMed ID: 33156019
[TBL] [Abstract][Full Text] [Related]
5. Vitiligo vs. hypopigmented mycosis fungoides (histopathological and immunohistochemical study, univariate analysis).
El-Darouti MA; Marzouk SA; Azzam O; Fawzi MM; Abdel-Halim MR; Zayed AA; Leheta TM
Eur J Dermatol; 2006; 16(1):17-22. PubMed ID: 16436337
[TBL] [Abstract][Full Text] [Related]
6. Possible mechanisms of hypopigmentation in lichen sclerosus.
Carlson JA; Grabowski R; Mu XC; Del Rosario A; Malfetano J; Slominski A
Am J Dermatopathol; 2002 Apr; 24(2):97-107. PubMed ID: 11979069
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory vitiligo-like macules that simulate hypopigmented mycosis fungoides.
Petit T; Cribier B; Bagot M; Wechsler J
Eur J Dermatol; 2003; 13(4):410-2. PubMed ID: 12948929
[TBL] [Abstract][Full Text] [Related]
8. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
9. Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets.
Seif El Nasr H; Shaker OG; Fawzi MM; El-Hanafi G
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):103-8. PubMed ID: 22151832
[TBL] [Abstract][Full Text] [Related]
10. Hypopigmented Interface T-Cell Dyscrasia and Hypopigmented Mycosis Fungoides: A Comparative Study.
Youssef R; Mahgoub D; Zeid OA; Abdel-Halim DM; El-Hawary M; Hussein MF; Morcos MA; Aboelfadl DM; Abdelkader HA; Abdel-Galeil Y; Abdel-Halim MRE
Am J Dermatopathol; 2018 Oct; 40(10):727-735. PubMed ID: 30188378
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory Vitiligo or Hypopigmented Mycosis Fungoides?
Gomez-Moyano E; Vera-Casaño A; Gamero AH; Sanz-Trelles A; Crespo-Erchiga V
J Pediatr Hematol Oncol; 2010 May; 32(4):338-9. PubMed ID: 20418787
[No Abstract] [Full Text] [Related]
12. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
[TBL] [Abstract][Full Text] [Related]
13. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
[TBL] [Abstract][Full Text] [Related]
14. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
[TBL] [Abstract][Full Text] [Related]
15. Hypopigmented mycosis fungoides.
Handfield-Jones SE; Smith NP; Breathnach SM
Clin Exp Dermatol; 1992 Sep; 17(5):374-5. PubMed ID: 1458652
[TBL] [Abstract][Full Text] [Related]
16. Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology.
Furlan FC; Sanches JA
An Bras Dermatol; 2013; 88(6):954-60. PubMed ID: 24474105
[TBL] [Abstract][Full Text] [Related]
17. Hypopigmented interface T-cell dyscrasia: a form of cutaneous T-cell dyscrasia distinct from hypopigmented mycosis fungoides.
Magro CM; Hagen JW; Crowson AN; Liu YC; Mihm M; Drucker NM; Yassin AH
J Dermatol; 2014 Jul; 41(7):609-17. PubMed ID: 24806661
[TBL] [Abstract][Full Text] [Related]
18. Lack of functionally active Melan-A(26-35)-specific T cells in the blood of HLA-A2+ vitiligo patients.
Adams S; Lowes MA; O'Neill DW; Schachterle S; Romero P; Bhardwaj N
J Invest Dermatol; 2008 Aug; 128(8):1977-80. PubMed ID: 18337837
[TBL] [Abstract][Full Text] [Related]
19. Hypopigmented mycosis fungoides versus mycosis fungoides with concomitant hypopigmented lesions: same disease or different variants of mycosis fungoides?
Furlan FC; Pereira BA; Sotto MN; Sanches JA
Dermatology; 2014; 229(3):271-4. PubMed ID: 25323446
[TBL] [Abstract][Full Text] [Related]
20. Hypopigmented mycosis fungoides: a clinical mimicker of vitiligo.
Tolkachjov SN; Comfere NI
J Drugs Dermatol; 2015 Feb; 14(2):193-4. PubMed ID: 25689815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
